The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Integrated biomarker study of neoadjuvant pepinemab and nivolumab in patients with resectable metastatic melanoma.
 
Michael C. Lowe
Research Funding - Delcath Systems (Inst); Vaccinex (Inst)
 
Brian Olson
No Relationships to Disclose
 
Anthony Martinez
No Relationships to Disclose
 
Jacklyn Hammons
No Relationships to Disclose
 
Keith A. Delman
No Relationships to Disclose
 
Melinda Lynne Yushak
No Relationships to Disclose
 
Melanie Allor
No Relationships to Disclose
 
Christine A. Reilly
No Relationships to Disclose
 
Crystal L. Mallow
No Relationships to Disclose
 
Elizabeth E. Evans
Employment - Vaccinex
Stock and Other Ownership Interests - Vaccinex
Patents, Royalties, Other Intellectual Property - Inventor on following patents: Treatment of cancer with a semaphorin-4d antibody in combination with an epigenetic modulating agent. U.S. Provisional Patent Application No. 62/473,731 Use of Semaphorin-4D inhibitory molecules in combination with an im (Inst)
 
Terrence Lee Fisher
Employment - Vaccinex
Stock and Other Ownership Interests - Vaccinex
Patents, Royalties, Other Intellectual Property - Patent author, Vaccinex, Inc.
 
Gregory B. Lesinski
Consulting or Advisory Role - ProDa
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Novartis (Inst); Vaccinex (Inst)
 
Ragini Reiney Kudchadkar
Honoraria - Array BioPharma; Bristol-Myers Squibb
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Immunocore; Novartis; Regeneron
Research Funding - Merck (Inst); Regeneron (Inst)